Relacorilant Maintains Consistent Survival Benefit in Platinum-Resistant Ovarian Cancer

Corcept Therapeutics announced new clinical data on May 30, 2026, demonstrating that the combination of Lifyorli (relacorilant) and nab-paclitaxel maintains an overall survival benefit for patients with platinum-resistant ovarian cancer, regardless of whether the patients had prior exposure to taxane-based therapies.

The findings were presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data indicate that the survival advantage provided by the combination therapy is consistent across all patient subgroups, including those who received taxanes shortly before starting the trial treatment.

Consistent Survival Outcomes Across Subgroups

Platinum-resistant ovarian cancer is characterized by a lack of response to platinum-based chemotherapy, leaving clinicians with limited treatment options. Traditionally, the efficacy of subsequent taxane treatments can be influenced by the timing and frequency of prior taxane use.

According to the data presented by Corcept, Lifyorli combined with nab-paclitaxel showed a sustained improvement in overall survival (OS) across the entire study population. This benefit remained statistically significant even in the subgroup of patients who had recent taxane exposure, a group that often faces more challenging prognostic outcomes.

The consistency of these results suggests that the therapeutic effect of relacorilant is not diminished by previous chemotherapy regimens, potentially broadening the eligible patient population for the drug if approved for this indication.

Mechanism of Action and Clinical Application

Lifyorli is a selective glucocorticoid receptor (GR) antagonist. In the context of oncology, the drug is designed to block the effects of cortisol, which is often elevated in cancer patients due to stress or the use of corticosteroid medications.

Elevated cortisol levels and GR activation have been linked to the promotion of tumor growth and the development of resistance to chemotherapy. By antagonizing these receptors, relacorilant aims to sensitize tumor cells to the effects of chemotherapy, such as nab-paclitaxel, thereby improving the effectiveness of the treatment.

The ASCO 2026 presentation focused on the ability of this combination to overcome resistance mechanisms in platinum-resistant settings, demonstrating that the GR antagonism provided by Lifyorli works in tandem with the cytotoxic effects of nab-paclitaxel to extend patient life.

Business and Market Implications

For Corcept Therapeutics, these results represent a strategic expansion of Lifyorli’s potential market. While the company has a history of focusing on cortisol-related disorders, the successful application of relacorilant in an oncology setting opens a significant new revenue stream in the high-demand ovarian cancer market.

The ability to maintain efficacy across all subgroups, specifically those with prior taxane use, reduces the risk of restrictive labeling by regulatory agencies. If the drug can be marketed for all patients with platinum-resistant ovarian cancer rather than a narrow subset, the total addressable market increases substantially.

The company’s presentation of this data at a major industry conference like ASCO serves to validate the clinical utility of the GR antagonist approach to a global audience of oncologists and healthcare providers.

Next Steps for Development

The presentation of the overall survival data is a critical milestone in the regulatory pathway for Lifyorli in the oncology space. Overall survival is generally considered the gold standard endpoint for regulatory approval in late-stage cancer trials.

Corcept is expected to use these findings to support its ongoing regulatory interactions and potential filings for the treatment of platinum-resistant ovarian cancer. The company has not yet provided a specific timeline for the next phase of regulatory submission, but the consistency of the subgroup data provides a stronger foundation for a broad indication request.